Elan Announces The Appointment Of Hans Peter Hasler As Chief Operating Officer
Elan Corporation, plc (NYSE:ELN) today announced the appointment of Hans Peter Hasler as Chief Operating Officer (“COO”) of the Company with effect from October 1, 2012. Mr. Hasler is currently a non-executive director of the Company and on his appointment as COO, he will retire from the board of directors of the Company. Mr. Hasler was appointed a director of Elan in September 2011. He is currently the chairman of HBM Bioventures AG and principal of HPH Management GmbH. Mr. Hasler served with Biogen Idec in a number of key executive leadership roles from 2001 to 2009, most recently as its COO responsible for all commercial operations, business development, medical affairs and Biogen International.
Elan’s Chairman, Robert Ingram, and CEO, Kelly Martin, commented “Hans Peter has made a significant contribution to our company as a non-executive board member over the last twelve months and will be a valuable addition to our executive team. With over 20 years of experience in the industry we are confident that as COO, Hans Peter will be instrumental in helping position Elan for long-term growth in the future. Elan will benefit from his wealth of experience and strong leadership skills and we look forward to working with him as our COO. Hans Peter will work closely with us and the board of directors on all strategic and operational aspects of the company”.
About Elan
Elan is a neuroscience focused biotechnology company committed to making
a difference in the lives of patients and their families by dedicating
itself to bringing innovations in science to fill significant unmet
medical needs that continue to exist around the world. For additional
information about Elan, please visit
http://www.elan.com.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
